The drug’s observed anti-inflammatory action (particularly its ability to inhibit production of the corticosteroid-resistant chemokine CXCL10 by LMs) suggests that add-on treatment with a JAK inhibitor might be a valuable anti-inflammatory strategy in chronic obstructive pulmonary disease, Th1-high asthma, and both viral and via non-viral ARDSs (including COVID-19). Here, CXCL10 is linked to chronic obstructive pulmonary disease.